Related Experiment Video
Updated: Aug 12, 2026
07:47
Experimental Human Pneumococcal Carriage
Published on: February 15, 2013
[Anti-pneumococcal vaccine: justifications and results]
Revue De Pneumologie Clinique
|January 1, 1997
Summary
Pneumococcal vaccination, including Pneumo 23, reduces overall pneumonia with bacteremia incidence, particularly in low-risk individuals. Its usefulness is demonstrated in specific high-risk groups, though not for all pneumonia types.
Area of Science:
- Medical Microbiology
- Immunology
- Vaccinology
Context:
- Pneumococci infections pose significant health risks, with invasive serotypes and antibiotic resistance necessitating preventive strategies.
- The 23-valent pneumococcal vaccine (Pneumo 23) has been available since 1983.
- Evaluating vaccine efficacy requires analyzing diverse study designs and patient populations.
Purpose:
- To assess the efficacy of the 23-valent pneumococcal vaccine (Pneumo 23) in preventing pneumococcal infections.
- To identify specific populations and conditions where pneumococcal vaccination demonstrates significant protective benefits.
- To review evidence regarding the vaccine's effectiveness against different types of pneumonia and bronchitis.
Summary:
- A meta-analysis of randomized studies indicated that pneumococcal vaccination reduces the incidence of pneumococcal pneumonia with bacteremia, with significant efficacy observed in low-risk subjects.
- Case-control and retrospective studies suggest vaccination is beneficial for individuals over 65 with moderate risks, post-splenectomy patients, those with sickle cell anemia, and individuals with respiratory failure or smokers.
- The vaccine's protective effect was not demonstrated against all-cause pneumonia or bronchitis. Antibiotic prophylaxis is recommended for at-risk children under two alongside vaccination.
Impact:
- Provides evidence-based recommendations for pneumococcal vaccination strategies in various at-risk populations.
- Highlights the limitations of current vaccines, particularly against non-bacteremic pneumonia and bronchitis.
- Informs clinical decision-making regarding the use of pneumococcal vaccines and associated prophylactic measures.
More Related Videos
Related Concept Videos
01:51Vaccinations
Overview
01:30Pneumonia I: Introduction
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia III: Complications and Assessment
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
01:14Atypical Pneumonia
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
01:29Respiratory Syncytial Virus Disease
Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
01:29Pneumonia I: Introduction
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...